GSK acquires Boston Pharmaceuticals’ efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
Where Today's News Shapes Tomorrow
February 20, 2026
Headlines
